Patient Preferences in the Treatment of Moderate-to-severe Atopic Dermatitis
DOI:
https://doi.org/10.2340/actadv.v104.24339Keywords:
Adult dermatology, patient-centered care, patient participation, patient preferences, treatment preferencesAbstract
Atopic dermatitis is a chronic, inflammatory skin disease. A variety of systemic treatments are available for patients with moderate-to-severe atopic dermatitis. The efficacy, safety and administration profile of these treatments vary, and determining the optimal treatment strategy may require weighing the benefits and drawbacks of therapies with diverse characteristics. This study used an online discrete choice experiment survey to investigate treatment preferences among adults with atopic dermatitis from Denmark, France, the UK, or Canada. Participants were identified through existing online panels. The survey included questions regarding different treatment attributes, defined based on currently approved treatments for moderate to severe atopic dermatitis. Treatment preferences were measured as the relative importance of different treatment attributes. A total of 713 respondents met the inclusion criteria and completed the survey. The discrete choice experiment identified a significant preference for avoiding the risk of severe adverse events, and for oral pill every day compared with biweekly injections. The time to full effect was not rated as being important. These findings suggest that patients with moderate-to-severe atopic dermatitis prioritize safety as most important, followed by ease of administration in their treatment preferences, while time to full effect and monitoring requirements were the least important attributes.
Downloads
References
Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Ann Allergy Asthma Immunol 2017; 119: 548-552.e3.
https://doi.org/10.1016/j.anai.2017.09.076 DOI: https://doi.org/10.1016/j.anai.2017.09.076
Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutrit Metab 2015; 66: 8-16.
https://doi.org/10.1159/000370220 DOI: https://doi.org/10.1159/000370220
Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States adults. J Allergy Clin Immunol Pract 2019; 7: 2699-2706.e7.
https://doi.org/10.1016/j.jaip.2019.05.055 DOI: https://doi.org/10.1016/j.jaip.2019.05.055
Boguniewicz M, Leung DYM. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation: Immune response in atopic dermatitis. Immunol Rev 2011; 242: 233-246.
https://doi.org/10.1111/j.1600-065X.2011.01027.x DOI: https://doi.org/10.1111/j.1600-065X.2011.01027.x
Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg JI. Atopic dermatitis yardstick update. Ann Allergy Asthma Immunol 2023; 130: 811-820.
https://doi.org/10.1016/j.anai.2023.03.010 DOI: https://doi.org/10.1016/j.anai.2023.03.010
Weidinger S, Novak N. Atopic dermatitis. The Lancet 2016; 387: 1109-1122.
https://doi.org/10.1016/S0140-6736(15)00149-X DOI: https://doi.org/10.1016/S0140-6736(15)00149-X
Boeri M, Sutphin J, Hauber B, Cappelleri JC, Romero W, Di Bonaventura M. Quantifying patient preferences for systemic atopic dermatitis treatments using a discrete-choice experiment. J Dermatol Treat 2020; 33: 1449-1458.
https://doi.org/10.1080/09546634.2020.1832185 DOI: https://doi.org/10.1080/09546634.2020.1832185
Bieber T, Paller AS, Kabashima K, Feely M, Rueda MJ, Ross Terres JA, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. Acad Dermatol Venereol 2022; 36: 1432-1449.
https://doi.org/10.1111/jdv.18225 DOI: https://doi.org/10.1111/jdv.18225
Silverberg JI, Thyssen JP, Fahrbach K, Mickle K, Cappelleri JC, Romero W, et al. Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. Acad Dermatol Venereol 2021; 35: 1797-1810.
https://doi.org/10.1111/jdv.17351 DOI: https://doi.org/10.1111/jdv.17351
Adtralza EMA label. [cited 2023 Apr 3]. Available from: https://www.ema.europa.eu/en/documents/product-information/adtralza-epar-product-information_en.pdf
de Bekker-Grob EW, Berlin C, Levitan B, Raza K, Christoforidi K, Cleemput I, et al. Giving patients' preferences a voice in medical treatment life cycle: the PREFER Public-Private Project. Patient 2017; 10: 263-266.
https://doi.org/10.1007/s40271-017-0222-3 DOI: https://doi.org/10.1007/s40271-017-0222-3
Li A, Zhang M, Yang Y, Zhang J, Xie X, Li X, et al. Patient-reported outcome (PRO) instruments for disease severity and quality of life in patients with atopic dermatitis: a systematic review of English and Chinese literature. Ann Transl Med; 2022; 10: 906.
https://doi.org/10.21037/atm-22-3164 DOI: https://doi.org/10.21037/atm-22-3164
Laba TL, Essue B, Kimman M, Jan S. Understanding patient preferences in medication nonadherence: a review of stated preference data. Patient 2015; 8: 385-395.
https://doi.org/10.1007/s40271-014-0099-3 DOI: https://doi.org/10.1007/s40271-014-0099-3
Guidance for Industry, Food and, Drug Administration Staff, and, Other Stakeholders. Patient Preference Information - Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling. 2016 [cited 2022 Nov 18]. Available from: https://www.fda.gov/media/92593/download
Lancsar E, Louviere J. Conducting discrete choice experiments to inform healthcare decision making: a user's guide. Pharmacoeconomics 2008; 26: 661-677.
https://doi.org/10.2165/00019053-200826080-00004 DOI: https://doi.org/10.2165/00019053-200826080-00004
Charman CR, Venn AJ, Williams HC. The Patient-Oriented Eczema Measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients' perspective. Arch Dermatol 2004; 140: 1513-1519.
https://doi.org/10.1001/archderm.140.12.1513 DOI: https://doi.org/10.1001/archderm.140.12.1513
Charman CR, Venn AJ, Ravenscroft JC, Williams HC. Translating Patient-Oriented Eczema Measure (POEM) scores into clinical practice by suggesting severity strata derived using anchor-based methods. Br J Dermatol 2013; 169: 1326-1332.
https://doi.org/10.1111/bjd.12590 DOI: https://doi.org/10.1111/bjd.12590
Ramboll. SurveyXact. [cited 2022 Nov 24]. Available from: https://www.surveyxact.dk/
Bridges JFP, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value in Health 2011; 14: 403-413.
https://doi.org/10.1016/j.jval.2010.11.013 DOI: https://doi.org/10.1016/j.jval.2010.11.013
Ryan M. Using conjoint analysis to elicit preferences for health care. BMJ 2000; 320: 1530-1533.
https://doi.org/10.1136/bmj.320.7248.1530 DOI: https://doi.org/10.1136/bmj.320.7248.1530
Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Mühlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health 2013; 16: 3-13.
https://doi.org/10.1016/j.jval.2012.08.2223 DOI: https://doi.org/10.1016/j.jval.2012.08.2223
Bylund S, Kobyletzki L, Svalstedt M, Svensson Å. Prevalence and incidence of atopic dermatitis: a systematic review. Acta Derm Venereol 2020; 100: adv00160.
https://doi.org/10.2340/00015555-3510 DOI: https://doi.org/10.2340/00015555-3510
Halling AS, Loft N, Silverberg JI, Guttman-Yassky E, Thyssen JP. Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol 2021; 84: 139-147.
https://doi.org/10.1016/j.jaad.2020.08.051 DOI: https://doi.org/10.1016/j.jaad.2020.08.051
Drugs.com. [cited 2023 Mar 7]. Tralokinumab FDA label. Available from: https://www.drugs.com/dosage/tralokinumab.html
Thomas C, Raibouaa A, Wollenberg A, Capron JP, Krucien N, Karn H, et al. Patient preferences for atopic dermatitis medications in the UK, France and Spain: a discrete choice experiment. BMJ Open 2022; 12: e058799.
https://doi.org/10.1136/bmjopen-2021-058799 DOI: https://doi.org/10.1136/bmjopen-2021-058799
Ervin C, Crawford R, Evans E, Feldman SR, Zeichner J, Zielinski MA, et al. Patient and caregiver preferences on treatment attributes for atopic dermatitis. J Dermatolog Treat 2022; 33: 2225-2233.
https://doi.org/10.1080/09546634.2021.1940810 DOI: https://doi.org/10.1080/09546634.2021.1940810
Published
How to Cite
License
Copyright (c) 2024 Mahreen Ameen, Raed Alhusayen, Henrik Brandi, Mette Bøgelund, Henrik H. Jensen, Signe B. Reitzel , Jacob P. Thyssen
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
